Scientists are increasingly examining retatrutide, a promising treatment created by Eli Lilly, as a possible advance in physique loss . Distinct from many earlier approaches, retatrutide is a double -action receptor targeting simultaneously GLP-1 and GIP, hormones that influence appetite and blo